JP2016523511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523511A5 JP2016523511A5 JP2016506657A JP2016506657A JP2016523511A5 JP 2016523511 A5 JP2016523511 A5 JP 2016523511A5 JP 2016506657 A JP2016506657 A JP 2016506657A JP 2016506657 A JP2016506657 A JP 2016506657A JP 2016523511 A5 JP2016523511 A5 JP 2016523511A5
- Authority
- JP
- Japan
- Prior art keywords
- pairs
- indicator
- region
- cancer cells
- loh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019085187A JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809105P | 2013-04-05 | 2013-04-05 | |
| US61/809,105 | 2013-04-05 | ||
| US201361913762P | 2013-12-09 | 2013-12-09 | |
| US61/913,762 | 2013-12-09 | ||
| PCT/US2014/033014 WO2014165785A2 (en) | 2013-04-05 | 2014-04-04 | Methods and materials for assessing homologous recombination deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085187A Division JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523511A JP2016523511A (ja) | 2016-08-12 |
| JP2016523511A5 true JP2016523511A5 (cg-RX-API-DMAC10.html) | 2017-03-16 |
| JP6625045B2 JP6625045B2 (ja) | 2019-12-25 |
Family
ID=51659359
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506657A Active JP6625045B2 (ja) | 2013-04-05 | 2014-04-04 | 相同組換え欠損を評価するための方法および材料 |
| JP2019085187A Active JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
| JP2020194936A Active JP7522643B2 (ja) | 2013-04-05 | 2020-11-25 | 相同組換え欠損を評価するための方法および材料 |
| JP2022169085A Active JP7641938B2 (ja) | 2013-04-05 | 2022-10-21 | 相同組換え欠損を評価するための方法および材料 |
| JP2025027653A Pending JP2025090619A (ja) | 2013-04-05 | 2025-02-25 | 相同組換え欠損を評価するための方法および材料 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085187A Active JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
| JP2020194936A Active JP7522643B2 (ja) | 2013-04-05 | 2020-11-25 | 相同組換え欠損を評価するための方法および材料 |
| JP2022169085A Active JP7641938B2 (ja) | 2013-04-05 | 2022-10-21 | 相同組換え欠損を評価するための方法および材料 |
| JP2025027653A Pending JP2025090619A (ja) | 2013-04-05 | 2025-02-25 | 相同組換え欠損を評価するための方法および材料 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20140363521A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3693475A1 (cg-RX-API-DMAC10.html) |
| JP (5) | JP6625045B2 (cg-RX-API-DMAC10.html) |
| AU (3) | AU2014248007B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2908745C (cg-RX-API-DMAC10.html) |
| DK (1) | DK2981624T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2777228T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT2981624T (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014165785A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| EP3225697A3 (en) | 2010-12-30 | 2017-11-22 | Foundation Medicine, Inc. | Optimization of multigene analysis of tumor samples |
| ES2768344T3 (es) | 2011-06-17 | 2020-06-22 | Myriad Genetics Inc | Métodos y materiales para evaluar el desequilibrio alélico |
| JP6325453B2 (ja) | 2011-12-21 | 2018-05-16 | ミリアド・ジェネティックス・インコーポレイテッド | ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| ES2687024T3 (es) | 2012-02-23 | 2018-10-23 | Children's Medical Center Corporation | Procedimientos para predecir la respuesta contra el cáncer |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| CA2931181C (en) | 2013-12-09 | 2023-01-24 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US10545151B2 (en) | 2014-02-21 | 2020-01-28 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| DK3686288T3 (da) | 2014-08-15 | 2023-05-22 | Myriad Genetics Inc | Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens |
| ES2989276T3 (es) * | 2014-12-05 | 2024-11-25 | Found Medicine Inc | Análisis multigénico de muestras tumorales |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| US20180148792A1 (en) | 2015-05-19 | 2018-05-31 | T.S. Sridhar | Method for Identification of a Deficient BRCA1 Function |
| CN115341033A (zh) * | 2015-11-03 | 2022-11-15 | 艾匹克科学公司 | 一种表征疾病异质性的方法 |
| WO2017106365A1 (en) * | 2015-12-14 | 2017-06-22 | Myriad Genetics, Inc. | Methods for measuring mutation load |
| US20190025312A1 (en) * | 2016-01-06 | 2019-01-24 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
| WO2017165270A1 (en) * | 2016-03-21 | 2017-09-28 | Myriad Genetics, Inc. | Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer |
| WO2017178509A1 (en) | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| WO2017191074A1 (en) * | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| US12062416B2 (en) | 2016-05-01 | 2024-08-13 | Genome Research Limited | Method of characterizing a DNA sample |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| KR20210035167A (ko) | 2018-06-11 | 2021-03-31 | 파운데이션 메디신 인코포레이티드 | 게놈 변경을 평가하기 위한 조성물 및 방법 |
| JPWO2020137076A1 (ja) * | 2018-12-28 | 2021-11-11 | 国立大学法人 東京大学 | Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法 |
| US10975445B2 (en) | 2019-02-12 | 2021-04-13 | Tempus Labs, Inc. | Integrated machine-learning framework to estimate homologous recombination deficiency |
| WO2021119311A1 (en) | 2019-12-10 | 2021-06-17 | Tempus Labs, Inc. | Systems and methods for predicting homologous recombination deficiency status of a specimen |
| CN114829624A (zh) * | 2019-12-16 | 2022-07-29 | 安捷伦科技有限公司 | 基因组瘢痕测定和相关方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN111883211B (zh) * | 2020-08-07 | 2021-04-23 | 张哲� | 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法 |
| CN111676277B (zh) * | 2020-08-12 | 2020-12-15 | 臻和(北京)生物科技有限公司 | 一种基于二代测序技术测定基因组不稳定的方法及试剂盒 |
| CN112164420B (zh) | 2020-09-07 | 2021-07-20 | 厦门艾德生物医药科技股份有限公司 | 一种基因组瘢痕模型的建立方法 |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| JP7585015B2 (ja) | 2020-12-04 | 2024-11-18 | 株式会社東芝 | 核酸構築物のセット、キット、検出方法及び薬剤効果予測方法 |
| US20240052423A1 (en) * | 2020-12-07 | 2024-02-15 | Pfizer Inc. | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
| CN114096681B (zh) * | 2021-01-10 | 2024-06-21 | 行动基因(智财)有限公司 | 同源重组缺失检测方法及其试剂组 |
| BE1029144B1 (fr) | 2021-02-25 | 2022-09-20 | Oncodna | Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé |
| CN112820351A (zh) * | 2021-03-01 | 2021-05-18 | 江苏医联生物科技有限公司 | 检测肿瘤患者的突变和hrd评分指导用药的方法 |
| AU2022299105A1 (en) * | 2021-06-25 | 2024-01-04 | Foundation Medicine, Inc. | System and method of classifying homologous repair deficiency |
| CA3240150A1 (en) * | 2021-12-08 | 2023-06-15 | Alexander Gutin | Methods and materials for assessing homologous recombination deficiency in breast cancer subtypes |
| KR102523938B1 (ko) * | 2022-02-04 | 2023-04-19 | 가톨릭대학교 산학협력단 | 상동 재조합 결핍증 예측 모델의 모델링 방법 |
| US20260139317A1 (en) | 2022-10-19 | 2026-05-21 | Vib Vzw | Method of Determining Loss of Heterozygosity Status of a Tumor |
| EP4792336A1 (en) | 2023-10-10 | 2026-08-19 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| EP4791901A1 (en) | 2023-10-10 | 2026-08-19 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| ZA928771B (en) | 1991-11-15 | 1993-09-08 | Smithkline Beecham Corp | Combination chemotherapy |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| US6887996B2 (en) | 2000-12-01 | 2005-05-03 | Guilford Pharmaceuticals Inc. | Compounds and their use |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| WO2005002508A2 (en) | 2003-06-11 | 2005-01-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| WO2005004805A2 (en) | 2003-07-02 | 2005-01-20 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| MXPA06000993A (es) | 2003-07-25 | 2006-08-31 | Cancer Rec Tech Ltd | Inhbidores triciclicos de parp. |
| CA2535762A1 (en) | 2003-08-13 | 2005-03-17 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| DE602006018299D1 (de) | 2005-06-30 | 2010-12-30 | Bionumerik Pharmaceuticals Inc | Platinanaloga mit monoazolligand |
| KR100925337B1 (ko) * | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| EP3327148B1 (en) | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| ES2704303T3 (es) * | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| ES2687024T3 (es) * | 2012-02-23 | 2018-10-23 | Children's Medical Center Corporation | Procedimientos para predecir la respuesta contra el cáncer |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
-
2014
- 2014-04-04 DK DK14779403.6T patent/DK2981624T3/da active
- 2014-04-04 EP EP19216740.1A patent/EP3693475A1/en active Pending
- 2014-04-04 ES ES14779403T patent/ES2777228T3/es active Active
- 2014-04-04 US US14/245,576 patent/US20140363521A1/en not_active Abandoned
- 2014-04-04 AU AU2014248007A patent/AU2014248007B2/en active Active
- 2014-04-04 CA CA2908745A patent/CA2908745C/en active Active
- 2014-04-04 JP JP2016506657A patent/JP6625045B2/ja active Active
- 2014-04-04 PT PT147794036T patent/PT2981624T/pt unknown
- 2014-04-04 EP EP14779403.6A patent/EP2981624B1/en active Active
- 2014-04-04 WO PCT/US2014/033014 patent/WO2014165785A2/en not_active Ceased
-
2017
- 2017-07-17 US US15/651,652 patent/US20180030544A1/en not_active Abandoned
-
2019
- 2019-04-26 JP JP2019085187A patent/JP7522539B2/ja active Active
-
2020
- 2020-06-17 AU AU2020204028A patent/AU2020204028B2/en active Active
- 2020-11-25 JP JP2020194936A patent/JP7522643B2/ja active Active
-
2021
- 2021-06-21 US US17/353,279 patent/US20210310079A1/en active Pending
-
2022
- 2022-08-04 AU AU2022211880A patent/AU2022211880B2/en active Active
- 2022-10-21 JP JP2022169085A patent/JP7641938B2/ja active Active
-
2025
- 2025-02-25 JP JP2025027653A patent/JP2025090619A/ja active Pending
- 2025-03-24 US US19/088,496 patent/US20250223655A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021112205A5 (cg-RX-API-DMAC10.html) | ||
| FI2794907T4 (fi) | Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi | |
| ES2946251T3 (es) | Métodos y materiales para evaluar la deficiencia de recombinación homóloga | |
| JP2015506678A5 (cg-RX-API-DMAC10.html) | ||
| ES2777228T3 (es) | Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer | |
| ES2862331T3 (es) | Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer | |
| US20180163271A1 (en) | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity | |
| Liu et al. | Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing | |
| US11028448B2 (en) | Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension | |
| Liao et al. | Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer | |
| CN108603231B (zh) | 检测癌症复发的方法 | |
| CN106480078A (zh) | 一组胃癌腹膜转移标志物及其用途 | |
| Shi et al. | Prognostic Model for Clear-cell Renal Cell Carcinoma Based on Natural Killer Cell-related Genes. | |
| Jiang et al. | Identification of a novel fusion gene (HLA-E and HLA-B) by RNA-seq analysis in esophageal squamous cell carcinoma | |
| Grimm et al. | Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer | |
| Gill | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies | |
| Perdrizet et al. | P2. 03-04 Next Generation Sequencing in Lung Cancer Using the Oncomine Comprehensive Assay: The Canadian Publicly Funded Experience | |
| Oláh | Learning from cancer to address COVID-19 | |
| NZ728326B2 (en) | Methods and materials for assessing homologous recombination deficiency | |
| NZ766822B2 (en) | Methods and materials for assessing homologous recombination deficiency | |
| KR20140012426A (ko) | 재발성 다형교아종 진단용 조성물 및 진단 방법 | |
| Richardson et al. | Homologous recombination deficiency (HRD) score predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer | |
| Fedorova et al. | The CpG island methylator phenotype (CIMP) in colorectal cancer is associated with energy metabolism alterations | |
| Gordon | Oligogenic combinations associated with breast cancer risk in women under 53 years of age C. Aston, D. Ralph, D. Lalo, S. Manjeshwar, BA Gramling, DC DeFreese, AD West, DE Branam, LF Thompson, MA Craft, et al. Hum Genet 2005; 116: 208–21 | |
| Sharma et al. | Spectrum of mutations identified in a 25-gene hereditary cancer panel for patients with breast cancer |